Quick Answer
Vicarious Surgical Inc. reported R&D Expense of $33.60 million for fiscal year 2025.
Vicarious Surgical Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $33.60M | -16.3% |
| 2024 | $40.16M | -15.6% |
| 2023 | $47.58M | +8.4% |
| 2022 | $43.90M | +99.0% |
| 2021 | $22.06M | +125.2% |
| 2020 | $9.80M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.99M | -26.0% | -11.7% |
| June 30, 2025 | $9.05M | -17.2% | -3.9% |
| March 31, 2025 | $9.41M | -5.5% | -12.8% |
| September 30, 2024 | $10.80M | -17.2% | -1.1% |
| June 30, 2024 | $10.92M | -14.1% | +9.6% |
| March 31, 2024 | $9.97M | -25.4% | -23.6% |
| September 30, 2023 | $13.04M | +7.6% | +2.6% |
| June 30, 2023 | $12.71M | +26.4% | -4.8% |
- Vicarious Surgical Inc. showed a decrease of -16.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Vicarious Surgical Inc.’s r&d expense has grown by 243.0% (from $9.80 million to $33.60 million).
- The most recent figure is from Vicarious Surgical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: